Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study investigating rivaroxaban to assess various outcomes of cancer patients with blood clots who are treated with an anticoagulant to better understand the treatment of VTE and the prevention of recurrent events in this patient population

Trial Profile

A study investigating rivaroxaban to assess various outcomes of cancer patients with blood clots who are treated with an anticoagulant to better understand the treatment of VTE and the prevention of recurrent events in this patient population

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Dec 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Cancer; Venous thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CALLISTO
  • Most Recent Events

    • 07 Dec 2015 According to a Janssen Pharmaceuticals media release, results from first 200 patients were presented at the 2015 American Society of Hematology (ASH) Annual Meeting.
    • 07 Dec 2015 Results from first 200 patients were published in a Janssen Pharmaceuticals media release.
    • 07 Dec 2015 Status changed from planning to recruiting, according to a Janssen Pharmaceuticals media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top